Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria:

WHO-confirmed AML, other than APL, with no standard treatment options available
Age 18 years or older

Relapsed or refractory (resistant) disease, as defined by standard criteria7

Relapsed: Bone marrow blasts ≥5%, reappearance of blasts in the blood, or development of extramedullary disease following achievement of CR/CRi/CRp/MLFS
Refractory (resistant): Failure to achieve CR/CRi/MLFS in subjects who survive ≥7 days following completion of initial treatment, with evidence of persistent leukemia by blood and/or bone marrow examination
>14 days since any prior therapy for AML excluding hydroxyurea
Willing and able to understand and voluntarily sign a written informed consent
Able to adhere to the study visit schedule and other protocol requirements
Women of childbearing potential must use an acceptable form of birth control for 28 days prior to beginning study treatment, through the duration of study treatment, and for 3 months after discontinuing study treatment.

Exclusion Criteria:

New York Heart Association Class III or IV heart failure
Unstable angina pectoris
Significant uncontrolled cardiac arrhythmias, including ventricular arrhythmias, congenital long QT syndrome, symptomatic atrial fibrillation, symptomatic bradycardia, right bundle branch block plus left anterior hemiblock or bifasicular block
QTc >500 ms, uncorrectable by managing electrolytes and medications, using the QTcF formula in Appendix D.
Active acute graft vs. host disease ≥ grade 2 or active extensive chronic GVHD
Relapse after allogeneic stem cell transplantation prior to post-transplant day 30
Active central nervous system (CNS) involvement of leukemia (lumbar puncture not required to rule out CNS involvement if not suspected)
Uncontrolled psychiatric illness that would limit compliance with requirements
Pregnant or breast feeding females

Laboratory abnormalities:

Either creatinine >2.0 mg/dL or creatinine clearance <30 mL/min
Total bilirubin > 3 x institutional upper limit of normal (ULN) (unless documented Gilbert's syndrome)
AST or ALT > 3 x institutional ULN, unless felt to be due to disease involvement
Other medical or psychiatric illness or organ dysfunction or laboratory abnormality which, in the opinion of the investigator, would compromise the subject's safety or interfere with data interpretation.